Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Countries and organisations
Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.
Free access · No subscription for research tools or data exports
Explore registry geography and organisations
6 trials match this view; 8 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 260 across 6 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Countries with reported trial locations
Sponsors recorded in this index
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsDepression · Anxiety · Cancer | M.D. Anderson Cancer Center PHASE2 | Recruiting Registry updated 2026-08-12 | 20 ESTIMATED | 2025-05-23 2027-03-31 2029-03-31 | |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerCancer · Major Depressive Disorder | Sunstone Medical PHASE2 | Active, not recruiting Registry updated 2026-05-06 | 56 ESTIMATED | 2023-10-23 2027-04-30 2027-11-01 | |
| A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.Adjustment Disorder · Adjustment Disorder With Anxious Mood · Cancer · Cancer Cachexia · Cancer of Endometrium · Cancer of Kidney · Cancer of Prostate · Cancer of the Breast · Cancer of Stomach · Cancer Melanoma Skin · Cancer Pancreas | Psyence Australia Pty Ltd PHASE2 | Recruiting Registry updated 2026-03-03 | 87 ESTIMATED | 2025-10-01 2026-12-30 2027-07-30 | |
| A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With CancerCancer | University of Utah EARLY_PHASE1 | Completed Registry updated 2024-03-20 | 12 ACTUAL | 2021-10-04 2022-06-11 2022-12-16 | |
| Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer PatientsCancer | NYU Langone Health EARLY_PHASE1 | Completed Registry updated 2020-10-20 | 29 ACTUAL | 2009-02 2018-09-06 2018-09-06 | |
| Psychopharmacology of Psilocybin in Cancer PatientsDepressive Symptoms · Anxiety · Cancer | Johns Hopkins University PHASE2 | Completed Registry updated 2018-07-19 | 56 ACTUAL | 2007-04 2014-12 2016-12 |
Reported research facilities
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States
Sunstone Medical, PCRockville, Maryland, United States
Mind Medicine Australia ClinicAbbotsford, Victoria, Australia
Paratus Clinical Research MelbourneNorthcote, Victoria, Australia
Empax CentreLeederville, Western Australia, Australia
Huntsman Cancer InstituteSalt Lake City, Utah, United States
NYU College of Dentistry Bluestone Center for Clinical ResearchNew York, New York, United States
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview CampusBaltimore, Maryland, United States
This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.